Clinical Evidence on Particle Radiation, DNA Damage Response Inhibitors, and Immunotherapy for Mismatch Repair-Proficient Rectal Cancer
Particle radiation and/or DDRi have significant preclinical evidence of immunostimulatory effects in pMMR rectal adenocarcinoma and increase response rates to immunotherapy (presented in the companion manuscript). Despite strong preclinical evidence and rationale, clinical trials including all three modalities are scarce. Existing evidence suggests a potential benefit based on extrapolation from photon-based studies and supports prospective evaluation with careful attention to treatment-related toxicity, which remains a concern.
Authors
- Jake A. Kloeber (ORCID: https://orcid.org/0000-0002-6646-564X)
- Yasamin Sharifzadeh (ORCID: https://orcid.org/0000-0003-3269-3107)
- Alexander D. Sherry (ORCID: https://orcid.org/0000-0001-5115-1691)
- Robert W. Mutter (ORCID: https://orcid.org/0000-0002-9430-7323)
- Cameron M. Callaghan (ORCID: https://orcid.org/0000-0001-9795-1424)
- Michael G. Haddock (ORCID: https://orcid.org/0000-0001-8966-744X)
- Sonja Dragojevic (ORCID: https://orcid.org/0000-0003-3971-8530)
- Kenneth W. Merrell (ORCID: https://orcid.org/0000-0002-3831-5644)
- Zhenkun Lou (ORCID: https://orcid.org/0000-0003-1938-3091)
- Jethwa Krishan
- Cristian Salazar-Vilches
- Daniel Ebner
- Christopher L. Hallemeier
- Jasvinder Singh
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-17
- DOI
- https://doi.org/10.3390/cancers18040652
- Citations
- 1
- Primary Topic
- Radiation Therapy and Dosimetry
- Type
- article
- Field-Weighted Citation Impact
- 36.44